Keywords
Last Name
Institution

DAVID M SPENCER

TitleVisiting Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pathology & Immunology
DivisionImmunology
AddressONE BAYLOR PLAZA, MAIL STOP 245
Houston TX 77030
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S. Inducible activation of MyD88 and CD40 in CAR T-cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov. 2017 Aug 11. PMID: 28801306.
      View in: PubMed
    2. Foster AE, Mahendravada A, Shinners NP, Chang WC, Crisostomo J, Lu A, Khalil M, Morschl E, Shaw JL, Saha S, Duong MT, Collinson-Pautz MR, Torres DL, Rodriguez T, Pentcheva-Hoang T, Bayle JH, Slawin KM, Spencer DM. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40. Mol Ther. 2017 Jul 08. PMID: 28697888.
      View in: PubMed
    3. Sonpavde G, McMannis JD, Bai Y, Seethammagari MR, Bull JMC, Hawkins V, Dancsak TK, Lapteva N, Levitt JM, Moseley A, Spencer DM, Slawin KM. Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. Cancer Immunol Immunother. 2017 Jun 12. PMID: 28608115.
      View in: PubMed
    4. Ono N, Murakami K, Chan O, Hall H, Elford AR, Yen P, Calzascia T, Spencer DM, Ohashi PS, Dhanji S. Exposure to sequestered self-antigens in vivo is not sufficient for the induction of autoimmune diabetes. PLoS One. 2017; 12(3):e0173176. PMID: 28257518.
      View in: PubMed
    5. Collinson-Pautz MR, Slawin KM, Levitt JM, Spencer DM. MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity. PLoS One. 2016; 11(10):e0164547. PMID: 27741278.
      View in: PubMed
    6. Rushworth D, Alpert A, Santana-Carrero R, Olivares S, Spencer D, Cooper LJ. Antithymidylate resistance enables transgene selection and cell survival for T cells in the presence of 5-fluorouracil and antifolates. Gene Ther. 2016 Feb; 23(2):119-28. PMID: 26273805.
      View in: PubMed
    7. Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13. PMID: 25977584.
      View in: PubMed
    8. Barese CN, Felizardo TC, Sellers SE, Keyvanfar K, Di Stasi A, Metzger ME, Krouse AE, Donahue RE, Spencer DM, Dunbar CE. Regulated apoptosis of genetically modified hematopoietic stem and progenitor cells via an inducible caspase-9 suicide gene in rhesus macaques. Stem Cells. 2015 Jan; 33(1):91-100. PMID: 25330775; PMCID: PMC4270878.
    9. Wu C, Hong SG, Winkler T, Spencer DM, Jares A, Ichwan B, Nicolae A, Guo V, Larochelle A, Dunbar CE. Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies. Mol Ther Methods Clin Dev. 2014; 1:14053. PMID: 26052521.
      View in: PubMed
    10. Kemnade JO, Seethammagari M, Collinson-Pautz M, Kaur H, Spencer DM, McCormick AA. Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses in vivo. Vaccine. 2014 Jul 16; 32(33):4228-33. PMID: 24923637; PMCID: PMC4640454.
    11. Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905. PMID: 24753538; PMCID: PMC4064331.
    12. Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC, Riddell SR, Press OW. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One. 2013; 8(12):e82742. PMID: 24358223; PMCID: PMC3866194.
    13. Carstens JL, Shahi P, Van Tsang S, Smith B, Creighton CJ, Zhang Y, Seamans A, Seethammagari M, Vedula I, Levitt JM, Ittmann MM, Rowley DR, Spencer DM. FGFR1-WNT-TGF-? signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res. 2014 Jan 15; 74(2):609-20. PMID: 24305876; PMCID: PMC3905049.
    14. Valdez JM, Zhang L, Su Q, Dakhova O, Zhang Y, Shahi P, Spencer DM, Creighton CJ, Ittmann MM, Xin L. Notch and TGF? form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell. 2012 Nov 2; 11(5):676-88. PMID: 23122291; PMCID: PMC3490134.
    15. Spencer DM. Activation of antigen-exposed iMC-DCs at the "right place" and "right time" promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 01; 1(3):362-363. PMID: 22737615.
      View in: PubMed
    16. Kemnade JO, Seethammagari M, Narayanan P, Levitt JM, McCormick AA, Spencer DM. Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant. Mol Ther. 2012 Jul; 20(7):1462-71. PMID: 22434138; PMCID: PMC3392976.
    17. Shahi P, Park D, Pond AC, Seethammagari M, Chiou SH, Cho K, Carstens JL, Decker WK, McCrea PD, Ittmann MM, Rosen JM, Spencer DM. Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis. PLoS One. 2012; 7(1):e30814. PMID: 22303459; PMCID: PMC3267738.
    18. Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, Xiao X, Tang J, Wang X, Liu P, Yang M, Xie Z, Wei W, Spencer DM, Xie X. Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy. J Gene Med. 2011 Dec; 13(12):680-91. PMID: 22009763.
      View in: PubMed
    19. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 3; 365(18):1673-83. PMID: 22047558; PMCID: PMC3236370.
    20. Rockey WM, Hernandez FJ, Huang SY, Cao S, Howell CA, Thomas GS, Liu XY, Lapteva N, Spencer DM, McNamara JO, Zou X, Chen SJ, Giangrande PH. Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther. 2011 Oct; 21(5):299-314. PMID: 22004414; PMCID: PMC3198747.
    21. Chiou SH, Shahi P, Wagner RT, Hu H, Lapteva N, Seethammagari M, Sun SC, Levitt JM, Spencer DM. The E3 ligase c-Cbl regulates dendritic cell activation. EMBO Rep. 2011 Sep; 12(9):971-9. PMID: 21799517; PMCID: PMC3166462.
    22. Shahi P, Seethammagari MR, Valdez JM, Xin L, Spencer DM. Wnt and Notch pathways have interrelated opposing roles on prostate progenitor cell proliferation and differentiation. Stem Cells. 2011 Apr; 29(4):678-88. PMID: 21308863; PMCID: PMC3148789.
    23. Narayanan P, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest. 2011 Apr; 121(4):1524-34. PMID: 21383499; PMCID: PMC3069772.
    24. Ramachandran IR, Song W, Lapteva N, Seethammagari M, Slawin KM, Spencer DM, Levitt JM. The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function. J Immunol. 2011 Apr 1; 186(7):3934-45. PMID: 21357539.
      View in: PubMed
    25. Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, Spencer DM, Dotti G, Wu MF, Liu H, Kenney S, Gottschalk S. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood. 2011 Apr 21; 117(16):4304-14. PMID: 21304103; PMCID: PMC3087480.
    26. Sun J, Dotti G, Huye LE, Foster AE, Savoldo B, Gramatges MM, Spencer DM, Rooney CM. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther. 2010 Nov; 18(11):2006-17. PMID: 20842106; PMCID: PMC2990520.
    27. Sonpavde G, Slawin KM, Spencer DM, Levitt JM. Emerging vaccine therapy approaches for prostate cancer. Rev Urol. 2010; 12(1):25-34. PMID: 20428291; PMCID: PMC2859139.
    28. Grider MH, Park D, Spencer DM, Shine HD. Lipid raft-targeted Akt promotes axonal branching and growth cone expansion via mTOR and Rac1, respectively. J Neurosci Res. 2009 Nov 1; 87(14):3033-42. PMID: 19530170.
      View in: PubMed
    29. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle. 2009 Feb 15; 8(4):580-8. PMID: 19182515.
      View in: PubMed
    30. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008 Oct 15; 68(20):8516-24. PMID: 18922926; PMCID: PMC2597580.
    31. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007 Dec; 12(6):559-71. PMID: 18068632.
      View in: PubMed
    32. Sonpavde G, Spencer DM, Slawin KM. Vaccine therapy for prostate cancer. Urol Oncol. 2007 Nov-Dec; 25(6):451-9. PMID: 18047951.
      View in: PubMed
    33. Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 2007 Nov 1; 67(21):10528-37. PMID: 17974997.
      View in: PubMed
    34. Dong Z, Zeitlin BD, Song W, Sun Q, Karl E, Spencer DM, Jain HV, Jackson T, Núñez G, Nör JE. Level of endothelial cell apoptosis required for a significant decrease in microvessel density. Exp Cell Res. 2007 Oct 1; 313(16):3645-57. PMID: 17720154; PMCID: PMC2080879.
    35. Shah VR, Koster MI, Roop DR, Spencer DM, Wei L, Li Q, Schwartz RJ, Chang J. Double-inducible gene activation system for caspase 3 and 9 in epidermis. Genesis. 2007 Apr; 45(4):194-9. PMID: 17417788; PMCID: PMC2566959.
    36. Bins AD, van Rheenen J, Jalink K, Halstead JR, Divecha N, Spencer DM, Haanen JB, Schumacher TN. Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnol. 2007; 7:2. PMID: 17201912; PMCID: PMC1779781.
    37. Danese S, Sans M, Spencer DM, Beck I, Doñate F, Plunkett ML, de la Motte C, Redline R, Shaw DE, Levine AD, Mazar AP, Fiocchi C. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut. 2007 Jun; 56(6):855-62. PMID: 17170016; PMCID: PMC1954843.
    38. Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer DM. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol. 2006 Dec; 24(12):1581-90. PMID: 17143278.
      View in: PubMed
    39. Seethammagari MR, Xie X, Greenberg NM, Spencer DM. EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Res. 2006 Jun 15; 66(12):6199-209. PMID: 16778194.
      View in: PubMed
    40. Nikitina EY, Desai SA, Zhao X, Song W, Luo AZ, Gangula RD, Slawin KM, Spencer DM. Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res. 2005 May 15; 65(10):4309-19. PMID: 15899823.
      View in: PubMed
    41. Straathof KC, Pulè MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 1; 105(11):4247-54. PMID: 15728125; PMCID: PMC1895037.
    42. Zhou Z, Flesken-Nikitin A, Levine CG, Shmidt EN, Eng JP, Nikitina EY, Spencer DM, Nikitin AY. Suppression of melanotroph carcinogenesis leads to accelerated progression of pituitary anterior lobe tumors and medullary thyroid carcinomas in Rb+/- mice. Cancer Res. 2005 Feb 1; 65(3):787-96. PMID: 15705875.
      View in: PubMed
    43. Hanks BA, Jiang J, Singh RA, Song W, Barry M, Huls MH, Slawin KM, Spencer DM. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med. 2005 Feb; 11(2):130-7. PMID: 15665830.
      View in: PubMed
    44. Xie X, Luo Z, Slawin KM, Spencer DM. The EZC-prostate model: noninvasive prostate imaging in living mice. Mol Endocrinol. 2004 Mar; 18(3):722-32. PMID: 14684850.
      View in: PubMed
    45. Kazansky AV, Spencer DM, Greenberg NM. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res. 2003 Dec 15; 63(24):8757-62. PMID: 14695191.
      View in: PubMed
    46. Freeman KW, Welm BE, Gangula RD, Rosen JM, Ittmann M, Greenberg NM, Spencer DM. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res. 2003 Dec 1; 63(23):8256-63. PMID: 14678983.
      View in: PubMed
    47. Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen JM, Ittmann M, Greenberg NM, Spencer DM. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res. 2003 Oct 1; 63(19):6237-43. PMID: 14559809.
      View in: PubMed
    48. Pownall ME, Welm BE, Freeman KW, Spencer DM, Rosen JM, Isaacs HV. An inducible system for the study of FGF signalling in early amphibian development. Dev Biol. 2003 Apr 1; 256(1):89-99. PMID: 12654294.
      View in: PubMed
    49. Shariat SF, Kattan MW, Erdamar S, Nguyen C, Scardino PT, Spencer DM, Wheeler TM, Slawin KM. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol. 2003 Apr 1; 21(7):1223-31. PMID: 12663708.
      View in: PubMed
    50. Straathof KC, Spencer DM, Sutton RE, Rooney CM. Suicide genes as safety switches in T lymphocytes. Cytotherapy. 2003; 5(3):227-30. PMID: 12850790.
      View in: PubMed
    51. Chen M, Orozco A, Spencer DM, Wang J. Activation of initiator caspases through a stable dimeric intermediate. J Biol Chem. 2002 Dec 27; 277(52):50761-7. PMID: 12399450.
      View in: PubMed
    52. Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM, Slawin KM. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002 Oct 15; 62(20):5974-9. PMID: 12384565.
      View in: PubMed
    53. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol. 2002 May 13; 157(4):703-14. PMID: 12011115; PMCID: PMC2173854.
    54. Li B, Desai SA, MacCorkle-Chosnek RA, Fan L, Spencer DM. A novel conditional Akt 'survival switch' reversibly protects cells from apoptosis. Gene Ther. 2002 Feb; 9(4):233-44. PMID: 11896462.
      View in: PubMed
    55. Spencer DM, Veldman GM, Banerjee S, Willis J, Levine AD. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology. 2002 Jan; 122(1):94-105. PMID: 11781285.
      View in: PubMed
    56. Xie X, Zhao X, Liu Y, Zhang J, Matusik RJ, Slawin KM, Spencer DM. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res. 2001 Sep 15; 61(18):6795-804. PMID: 11559553.
      View in: PubMed
    57. Spencer DM. Gene therapy 2001: Pandora's ecdysis. Trends Genet. 2001 Apr; 17(4):183-5. PMID: 11357823.
      View in: PubMed
    58. Xie X, Zhao X, Liu Y, Young CY, Tindall DJ, Slawin KM, Spencer DM. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum Gene Ther. 2001 Mar 20; 12(5):549-61. PMID: 11268287.
      View in: PubMed
    59. Shariat SF, Desai S, Song W, Khan T, Zhao J, Nguyen C, Foster BA, Greenberg N, Spencer DM, Slawin KM. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. Cancer Res. 2001 Mar 15; 61(6):2562-71. PMID: 11289132.
      View in: PubMed
    60. Spencer DM. Developments in suicide genes for preclinical and clinical applications. Curr Opin Mol Ther. 2000 Aug; 2(4):433-40. PMID: 11249774.
      View in: PubMed
    61. Fan L, Freeman KW, Khan T, Pham E, Spencer DM. Improved artificial death switches based on caspases and FADD. Hum Gene Ther. 1999 Sep 20; 10(14):2273-85. PMID: 10515447.
      View in: PubMed
    62. MacCorkle RA, Freeman KW, Spencer DM. Synthetic activation of caspases: artificial death switches. Proc Natl Acad Sci U S A. 1998 Mar 31; 95(7):3655-60. PMID: 9520421; PMCID: PMC19891.
    63. Spencer DM, Belshaw PJ, Chen L, Ho SN, Randazzo F, Crabtree GR, Schreiber SL. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Curr Biol. 1996 Jul 1; 6(7):839-47. PMID: 8805308.
      View in: PubMed
    64. Spencer DM. Creating conditional mutations in mammals. Trends Genet. 1996 May; 12(5):181-7. PMID: 8984733.
      View in: PubMed
    SPENCER's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _